AI Therapeutics announces start of phase II trial of LAM-002A to treat Covid-19 patients

This article was originally published here

AI Therapeutics is a biopharmaceutical company that develops novel therapies identified through a proprietary artificial intelligence algorithm for matching drugs to new indications (Guardian Angel). The randomized, double-blind,

The post AI Therapeutics announces start of phase II trial of LAM-002A to treat Covid-19 patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply